NasdaqCM - Delayed Quote USD

GlycoMimetics, Inc. (GLYC)

0.2402
-0.0023
(-0.95%)
At close: May 9 at 4:00:00 PM EDT
0.2560
+0.02
+(6.58%)
After hours: May 9 at 6:26:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
10
75
1,159.7670
Operating Expense
32,508.7560
32,508.7560
39,284.6560
47,477.8790
64,606.9720
Operating Income
-32,508.7560
-32,508.7560
-39,274.6560
-47,402.8790
-63,447.2050
Net Non Operating Interest Income Expense
935.2750
935.2750
2,375.8730
714.5200
19.7680
Other Income Expense
-6,305.3590
-6,305.3590
--
--
--
Pretax Income
-37,878.8400
-37,878.8400
-36,898.7830
-46,688.3590
-63,427.4370
Net Income Common Stockholders
-37,879.1580
-37,879.1580
-36,899.4200
-46,688.8020
-63,427.4370
Diluted NI Available to Com Stockholders
-37,879.1580
-37,879.1580
-36,899.4200
-46,688.8020
-63,427.4370
Basic EPS
-0.59
-0.59
-0.58
-0.89
-1.23
Diluted EPS
-0.59
-0.59
-0.58
-0.89
-1.23
Basic Average Shares
64,477.2490
64,477.2490
63,342.4650
52,531.1730
51,453.2940
Diluted Average Shares
64,477.2490
64,477.2490
63,342.4650
52,531.1730
51,453.2940
Total Operating Income as Reported
-40,039.3780
-40,039.3780
-39,275.2930
-47,403.3220
-63,447.2050
Total Expenses
32,508.7560
32,508.7560
39,284.6560
47,477.8790
64,606.9720
Net Income from Continuing & Discontinued Operation
-37,879.1580
-37,879.1580
-36,899.4200
-46,688.8020
-63,427.4370
Normalized Income
-31,573.7990
-31,573.7990
-36,899.4200
-46,688.8020
-63,427.4370
Interest Income
935.2750
935.2750
2,375.8730
714.5200
19.7680
Net Interest Income
935.2750
935.2750
2,375.8730
714.5200
19.7680
EBIT
-32,508.7560
-32,508.7560
-39,274.6560
-47,402.8790
-63,447.2050
EBITDA
-32,473.5820
-32,473.5820
-39,121.3550
-47,195.7340
-63,182.6050
Reconciled Depreciation
35.1740
35.1740
153.3010
207.1450
264.6000
Net Income from Continuing Operation Net Minority Interest
-37,879.1580
-37,879.1580
-36,899.4200
-46,688.8020
-63,427.4370
Total Unusual Items Excluding Goodwill
-6,305.3590
-6,305.3590
0
--
--
Total Unusual Items
-6,305.3590
-6,305.3590
0
--
--
Normalized EBITDA
-26,168.2230
-26,168.2230
-39,121.3550
-47,195.7340
-63,182.6050
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/10/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MGNX MacroGenics, Inc.
1.4300
-7.14%
 
MRSN Mersana Therapeutics, Inc.
0.3189
-4.81%
 
AZTR Azitra, Inc.
0.2950
-0.97%
 
CDTX Cidara Therapeutics, Inc.
18.63
-2.72%
 
SNSE Sensei Biotherapeutics, Inc.
0.3600
-4.41%
 
KALA KALA BIO, Inc.
3.4200
-0.29%
 
ASMB Assembly Biosciences, Inc.
12.24
+4.97%
 
PASG Passage Bio, Inc.
0.3292
-5.02%
 
INAB IN8bio, Inc.
0.1574
-6.25%
 
IMCR Immunocore Holdings plc
28.40
-4.67%